オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

factors group australia pty ltd - glutamine, quantity: 16.667 mg/g; magnesium citrate, quantity: 302.184 mg/g (equivalent: magnesium, qty 48.833 mg/g); riboflavin, quantity: 1.667 mg/g; heavy magnesium oxide, quantity: 1.9353 mg/g (equivalent: magnesium, qty 1.167 mg/g); pyridoxal 5-phosphate monohydrate, quantity: 1.3054 mg/g (equivalent: pyridoxine, qty 0.833 mg/g); ascorbic acid, quantity: 8.33 mg/g - powder - excipient ingredients: xylitol; hypromellose; citric acid; steviol glycosides; flavour - maintain/support body electrolyte balance ; aids/assists teeth development ; helps enhance/promote teeth health ; maintain/support healthy body tissues ; maintain/support body tissue repair/regeneration ; helps enhance/promote bone health ; aids/assists healthy bone development/growth/building ; maintain/support muscle health ; maintain/support muscle function ; aid/assist/helps metabolism of (state vitamin/mineral/nutrient)

ニュージーランド - 英語 - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - lithium carbonate 250mg - capsule - 250 mg - active: lithium carbonate 250mg excipient: brilliant blue fcf gelatin lactose monohydrate magnesium stearate maize starch quinoline yellow sunset yellow fcf - · treatment of mania and hypomania. · treatment of some patients with recurrent bipolar depression, for which treatment with other antidepressants have been unsuccessful. · prophylactic treatment of recurrent affective disorders.

アイルランド - 英語 - HPRA (Health Products Regulatory Authority)

baxter healthcare limited - sodium chloride - solution for infusion - 0.9 percent weight/volume - solutions affecting the electrolyte balance; electrolytes

アイルランド - 英語 - HPRA (Health Products Regulatory Authority)

baxter healthcare limited - sodium chloride ; glucose - solution for infusion - 0.45/5 percent weight/volume - solutions affecting the electrolyte balance; electrolytes with carbohydrates

アイルランド - 英語 - HPRA (Health Products Regulatory Authority)

baxter healthcare limited - sodium chloride; glucose monohydrate - solution for infusion - 0.18/4 %w/v - electrolytes in combination with other drugs

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - potassium chloride, quantity: 2.98 g/l; sodium chloride, quantity: 9 g/l - injection, intravenous infusion - excipient ingredients: water for injections; hydrochloric acid - the baxter potassium chloride and sodium chloride intravenous infusion is indicated as a source of water and to restore electrolyte balance as required by the patient's clinical condition, such as hypokalaemia.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - zoledronic acid monohydrate, quantity: 4.264 mg (equivalent: zoledronic acid, qty 4 mg) - injection, concentrated - excipient ingredients: sodium citrate dihydrate; mannitol; water for injections - zoledronic acid accord is indicated:,for the prevention of skeletal-related events (pathological fracture, spinal cord compression, radiation to bone or surgery to bone) in patients with advanced malignancies involving bone.,for treatment of tumour-induced hypercalcaemia.,as an adjunct to adjuvant treatment for women with early breast cancer who are in established menopause.

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

redpharm drug, inc. - phenytoin sodium (unii: 4182431bjh) (phenytoin - unii:6158tkw0c5) - phenytoin sodium 100 mg - phenytoin is indicated for the control of tonic-clonic (grand mal) and psychomotor (temporal lobe) seizures and prevention and treatment of seizures occurring during or following neurosurgery. phenytoin serum level determinations may be necessary for optimal dosage adjustments (see dosage and administrationand clinical pharmacologysections). phenytoin is contraindicated in those patients with a history of hypersensitivity to phenytoin, its inactive ingredients, or other hydantoins. coadministration of phenytoin sodium is contraindicated with delavirdine due to potential for loss of virologic response and possible resistance to delavirdine or to the class of non-nucleoside reverse transcriptase inhibitors.

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

cardinal health - phenytoin sodium (unii: 4182431bjh) (phenytoin - unii:6158tkw0c5) - phenytoin sodium 100 mg - extended phenytoin sodium capsules, usp are indicated for the control of generalized tonic-clonic (grand mal) and psychomotor (temporal lobe) seizures and prevention and treatment of seizures occurring during or following neurosurgery. phenytoin serum level determinations may be necessary for optimal dosage adjustments (see dosage and administration and clinical pharmacology). extended phenytoin sodium capsules are contraindicated in those patients with a history of hypersensitivity to phenytoin, its inactive ingredients, or other hydantoins. coadministration of phenytoin is contraindicated with delavirdine due to potential for loss of virologic response and possible resistance to delavirdine or to the class of non-nucleoside reverse transcriptase inhibitors.

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

cardinal health 107, llc - lithium carbonate (unii: 2bmd2gna4v) (lithium cation - unii:8h8z5uer66) - lithium carbonate 300 mg - lithium is a mood-stabilizing agent indicated as monotherapy for the treatment of bipolar i disorder: lithium is contraindicated in patients with known hypersensitivity to any inactive ingredient in the lithium carbonate tablet or capsule or lithium citrate products [see adverse reactions (6)]. risk summary: lithium may cause harm when administered to a pregnant woman. early voluntary reports to international birth registries suggested an increase in cardiovascular malformations, especially for ebstein’s anomaly, with first trimester use of lithium. subsequent case-control and cohort studies indicate that the increased risk for cardiac malformations is likely to be small; however, the data are insufficient to establish a drug-associated risk. there are concerns for maternal and/or neonatal lithium toxicity during late pregnancy and the postpartum period [see clinical considerations]. published animal developmental and toxicity studies in mice and rats report an increased incidence of fetal mortality, decreas